Outcomes from patients with presumed drug resistant tuberculosis in five reference centers in Brazil by Ramalho, D.M.P et al.
RESEARCH ARTICLE Open Access
Outcomes from patients with presumed
drug resistant tuberculosis in five reference
centers in Brazil
D. M. P. Ramalho1, P. F. C. Miranda1, M. K. Andrade1,2, T. Brígido3, M. P. Dalcolmo2, E. Mesquita4, C. F. Dias5,
A. N. Gambirasio6, J. Ueleres Braga2, A. Detjen7, P. P. J. Phillips9, I. Langley8, P. I. Fujiwara7, S. B. Squire8,
M. M. Oliveira1, A. L. Kritski1* and for Rede-TB Study group
Abstract
Background: The implementation of rapid drug susceptibility testing (DST) is a current global priority for TB
control. However, data are scarce on patient-relevant outcomes for presumptive diagnosis of drug-resistant
tuberculosis (pDR-TB) evaluated under field conditions in high burden countries.
Methods: Observational study of pDR-TB patients referred by primary and secondary health units. TB reference
centers addressing DR-TB in five cities in Brazil. Patients age 18 years and older were eligible if pDR-TB, culture
positive results for Mycobacterium tuberculosis and, if no prior DST results from another laboratory were used by a
physician to start anti-TB treatment. The outcome measures were median time from triage to initiating appropriate
anti-TB treatment, empirical treatment and, the treatment outcomes.
Results: Between February,16th, 2011 and February, 15th, 2012, among 175 pDR TB cases, 110 (63.0%) confirmed TB
cases with DST results were enrolled. Among study participants, 72 (65.5%) were male and 62 (56.4%) aged 26 to
45 years. At triage, empirical treatment was given to 106 (96.0%) subjects. Among those, 85 were treated with first
line drugs and 21 with second line. Median time for DST results was 69.5 [interquartile - IQR: 35.7–111.0] days and,
for initiating appropriate anti-TB treatment, the median time was 1.0 (IQR: 0–41.2) days. Among 95 patients that
were followed-up during the first 6 month period, 24 (25.3%; IC: 17.5%–34.9%) changed or initiated the treatment
after DST results: 16/29 MDRTB, 5/21 DR-TB and 3/45 DS-TB cases. Comparing the treatment outcome to DS-TB
cases, MDRTB had higher proportions changing or initiating treatment after DST results (p = 0.01) and favorable
outcomes (p = 0.07).
Conclusions: This study shows a high rate of empirical treatment and long delay for DST results. Strategies to
speed up the detection and early treatment of drug resistant TB should be prioritized.
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Background
In 2015, WHO estimates that there were about 580,000
newly eligible for multidrug resistant tuberculosis
(MDR-TB) treatment. Nevertheless, only 125,000 (20%)
were enrolled. Approximately 60% of them occurred in
Brazil, China, India, the Russian Federation, South Africa,
Indonesia and Nigeria [1, 2]. Low rates of treatment
completion or cure (58 to 67%) in MDR-TB have been de-
scribed in a recent systematic reviews and meta-analyses
[3–6]. In order to respond more effectively to the emer-
gence of co-infection with TB and HIV and MDR-TB
globally, WHO has recommended new TB diagnostic
technologies, and most recently, rapid drug susceptibility
testing using molecular Line Probe Assays or Xpert MTB
RIF [7, 8]. The implementation of these techniques should
help programs to cope with the current clinical manage-
ment demands and also may help implementation of the
new anti-TB regimens that are in the pipeline.
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However, only a handful studies of the clinical impact
on adult patients with a presumed diagnosis of drug-
resistant tuberculosis (DR-TB) under field conditions in
high burden countries have been published regarding
the incorporation of new molecular technologies for TB
diagnosis.
Clinicians often start empirical TB treatment regimens
before culture and DST results become available. There
are several reasons for this, including the fact that culture
and DST results often take a long time and, sometimes,
do not even become available at all. This tradition of
empirical treatment has major implications on the im-
pact of newer and more sensitive diagnostic tests with
faster laboratory turnaround times [9–19].
In Brazil, much advancement in tuberculosis control in
the past 10 years have been described. Despite all this
progress, some very serious obstacles still need to be
addressed, including the low rate of detection of drug-
resistant TB and, also, the high morbidity and mortality
rate among MDR-TB cases [20]. In 2012, culture was
performed in 17.4% of TB cases reported. Only 28.1% of
those cases were previously treated TB cases. MTBDRplus,
Xpert™ MTB/Rif and MGIT960 have been commercialized
in Brazil, even though without being formally incorporated
into the public health system for the diagnosis of DR/
MDR-TB. Still, no data is available regarding the use of
these new diagnostic technologies in public TB reference
centers that manage DR/MDR-TB. In 2015, plans were
made to implement Xpert™ MTB/Rif in 90 municipalities,
covering 55% of the TB burden in the country. According
to this, it was expected that the detection of DR-TB cases
would increase 3 to 4 fold [21]. In order to assist the
impact evaluation of the incorporation of these new
molecular tests in the Brazilian Unified Health System
(SUS), the International Union Against Tuberculosis
and Lung Disease (The Union), through the TREAT TB
initiative, the Brazilian Network of Tuberculosis Research
(REDE-TB) and, the Academic Tuberculosis Program of
the Federal University of Rio de Janeiro, proposed a
crossover randomized pragmatic clinical trial (Register
N. RBR-4rprbd). Prior to this trial an observational and
descriptive baseline study among pDR-TB cases evalu-
ated in State Reference Centers has been completed
and is reported here. The objectives of this observational
study were to describe the clinical and laboratory manage-
ment of patients with pDR-TB and to describe risk factors
for DR/MDR-TB in patients attending DR-TB reference
centers in four Brazilian states.
Methods
Setting
Five sites from four different regions in Brazil were in-
cluded: inpatient services at Hospital Sanatorio Partenon-
Secretaria Estadual de Saúde do Rio Grande do Sul
(HU-SES-RGS), Hospital Messejana – Secretaria Estadual
do Ceará (HM-SES-CE), Instituto Estadual Ary Parreiras –
Secretaria Estadual do Rio de Janeiro (IETAP-SES-RJ),
outpatient services at Instituto Clemente Ferreira –
Secretaria Estadual de São Paulo (ICF-SES-SP) and,
Centro de Referência Hélio Fraga – Fundação Oswaldo
Cruz – Rio de Janeiro (CRPHF-Fiocruz-RJ).
Participants
Eligible participants were any patients aged 18 years and
older with cough for 3 weeks or more and, in accordance
with national guidance [22], with the presence of at least
one of the following social-clinical conditions defining
them as pDR TB at triage as follows: (a) suspected re-
treatment failure or previous treatment default; (b) HIV
seropositive subjects, c) close contact with smear positive
MDR-TB cases, (d) homeless or e) hospitalization in TB
reference centers. All participants gave written Informed
Consent. Subjects were excluded if they: (a) had DST
results (drug resistant or drug sensitive) from another
laboratory that had been used by an attending physician
to start anti-TB treatment at triage; (b) had no laboratory
assessment of the drug sensitivity confirmation of M. tu-
berculosis; (c) were harboring environmental mycobac-
teria and, (d) had no clinical and/or laboratory results
available in the medical records.
Data collection
Local study staff was comprised by one of each of the
following: a attending physician, a nurse, and a labora-
tory technician that belonged to the professional staff of
the Health Unit. During the study period, the survey was
carried out by the study staff on all presumed drug re-
sistant TB that fulfilled the eligibility criteria and was
attended consecutively in five Health Units. Prospectively,
routinely collected clinical data were extracted onto a
Study Form from patient registers and clinical records.
Patient registers contained information on all included
patients listed in consecutive order with name, age, sex,
address, phone number, type of patients (previous treat-
ment classification) and date of diagnosis (when available).
Also, it was collected from medical records, clinical
data, socio-demographics, previous treatment failures or
defaults, HIV status and hospitalization. Clinical samples
collected in Health Units were sent to a local laboratory
using standard practice. Laboratories issued results ac-
cording to routine procedures. All clinical samples from
these 5 sites were sent to the local Mycobacterial Labora-
tory for smear microscopy, culture, drug susceptibility
testing and identification at species level. Participants
were assigned to have their samples submitted to the
following routine bacteriological tests: BACTEC™ MGIT
960™ Mycobacterial Detection System (MGIT960) or
Lowenstein-Jensen (LJ)/Ogawa Kudo (OK) and Proportion
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Method (PM), according to the Brazilian Tuberculosis
National Guidelines [22]. Tests were performed accord-
ing to laboratory routine and the techniques used are
all fully described [23]. Clinical and radiological improve-
ment was judged by the attending physicians at each
site. TB patients received anti-TB treatment and clinical
follow-up from the attending physician as routinely
planned in the local algorithm. In summary, routine clin-
ical procedures were not affected by this study. Every
2 months, data monitoring research team checked all
clinical and laboratory data collected.
Case definition
Drug resistant (DR-TB) cases were defined as those har-
boring M. tb isolates resistant to one or more drugs and
multidrug resistant (MDR-TB) cases as resistant to at
least Rifampin-RIF and Isoniazid-INH. Drug sensitive
(DS-TB) cases were defined as those harboring M.tb iso-
lates susceptible to all first-line anti-TB drugs (RMP, INH,
Ethambutol-EMB, Pyrazinamid-PZA and Streptomycin-SM).
Empirical treatment was defined when at triage physicians
started TB treatment regimen before DST results were
available. Appropriate anti-TB treatment was defined
accordingly to the regimen prescribed by the attending
physician (matching DST results). Interim treatment
outcomes were evaluated after 6 months of enrollment
using available data from medical records. Retreatment
cases were grouped according to the outcome of previ-
ous treatment: cured, completed, defaulted or failed. A
patient was defined as cured when tested smear-
negative at treatment completion or, at least in one of
the previous test.
A completed treatment was defined as patients who
completed treatment but without smear microscopy
proof of cure. Persons who had treatment interruption
for two consecutive months or more were grouped as
defaulted. Those who remained smear-positive when
tested five or 6 months after initiation of their previous
treatment were defined as treatment failures. Clinical or
radiological improvement and/or culture conversion were
considered favorable TB treatment responses. Death from
any cause and default were unfavorable. Transferred care
cases which had no outcome data were all excluded.
Endpoints
A standard form was created in order to collect data re-
garding to the following timing: triage (screening visit),
sputum collection, DST result released by laboratory,
DST results seen by the physician and, initiation or change
of TB treatment regimen after DST results. The primary
endpoint was time from triage to initiation or change of
TB treatment regimen because of the DST result. The sec-
ondary endpoint was the proportion of favorable treatment
outcomes according to the initial empirical treatment regi-
men prescribed as follows: with first line drug regimen
(RIF + INH + EMB + PZA) or with second line drug regi-
men (ethionamide, levofloxacin, amikacyn/capreomicyin,
clofazimine).
Fig. 1 Flow diagram for Baseline Prove IT/5 sites 2011–2012. Amongst the 175 pacientes, 110 were included in the study, being 51(46%) drug
resistant and. Of these, 31(61%) are multi drug resistant.
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Table 1 Comparison of sociodemographic, behavior and clinical
characteristics of Presumed DR TB cases included and excluded in
the study
Variable Presumed DR TB cases P value
Included
N = 110
n (%)
Excluded
N = 65
n (%)
Demographic characteristics
Sex
Male 72(65.5) 44(67.7) p = 0.76
Female 38(34.5) 21(32.3)
Age
< 25 15(13.6) 12(18.5)
26–45 62(56.4) 34(52.3) p = 0.39
> 45 33(30.0) 19(29.2) p = 0.49
Marital status
Single 78(70.9) 49(75.4)
Married 32(29.1) 16(24.6) p = 0.52
Race
White 46(41.8) 18(27.7) p = 0.06
Non White 64(58.2) 47(72.3)
Schooling
< 8 years 98(89.1) 47(72.3)
> 8 years 9(8.2) 14(21.5) p = 0.08
IGN 3(2.7) 4(6.2) p = 0.17
Behaviour Characteristics
Smoker
Current/Ex 83(75.5) 45(69.2) p = 0.34
Never 25(22.7) 19(29.2)
IGN 2(1.8) 1(1.5)
Alcoholism (CAGE)
Yes 20(18.2) 13(20.0) p = 0.76
No 90(81.8) 52(80.0)
Admission hospital last 2 years
Yes 37(33.6) 26(40.0) p = 0.42
No 72(65.5) 39(60.0)
IGN 1(0.9) 0
Admission prision last 2 years
Yes 21(19.1) 14(21.5) p = 0.65
No 89(80.9) 50(76.9)
IGN 0 1(1.5)
Admission in Shelters last 2 years
Yes 8(7.3) 10(15.4) p = 0.09
No 100(90.9) 55(84.6)
IGN 2(1.8) 0
Table 1 Comparison of sociodemographic, behavior and clinical
characteristics of Presumed DR TB cases included and excluded in
the study (Continued)
Clinical, Radiological and Laboratory Characteristics
HIV testing result
Positive 12(10.9) 13(20.0) p = 0.26
Negative 61(55.5) 40(61.5)
IGN 37(33.6) 12(18.5)
Contact of pulm TB
Yes 55(50.0) 32(49.2) p = 0.52
No 45(40.9) 21(32.3)
IGN 10(9.1) 12(18.5)
TB in the past
Yes 87(79.1) 47(72.3) p = 0.42
No 22(20.0) 16(24.6)
IGN 1(0.9) 2(3.1)
Number treat in the past
= > 3 31(28.2) 13(20.0) p = 0.34
< 3 56(50.9) 34(52.3)
IGN 23(20.9) 18(27.7)
Form TB
Pulmonary 85(77.3) 46(70.8) p = 1.00
Pulmonary + Extrapulmonary 2(1.8) 1(1.5)
NA 23(20.9) 18(27.7)
Weight loss
Yes 75(68.2) 43(66.2) p = 0.78
No 35(31.8) 22(33.8)
Cough
Yes 101(91.8) 62(95.4) p = 0.88
No 7(6.4) 3(4.6)
IGN 2(1.8) 0
Expectoration
Yes 95(86.4) 53(81.5) p = 0.31
No 14(12.7) 12(18.5)
IGN 1(0.9) 0
Hemoptysis
Yes 26(23.6) 14(21.5) p = 0.76
No 83(75.5) 50(76.9)
IGN 1(0.9) 1(1.5)
Sweating
Yes 68(61.8) 38(58.5) p = 0.32
No 35(31.8) 27(41.5)
IGN 7(6.4) 0
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Statistical analysis
We compared socio-demographic and clinical character-
istics between included and excluded patients. Also, we
identified the factors associated with drug resistance. Ex-
ploratory analysis was carried out through dichotomous
outcomes based on the calculation proportion for all the
different groups. For continuous outcomes, median and
interquartiles were used. Sample distribution of time
periods from triage to DST results and to initiate or
change TB treatment were compared. Fisher’s Exact Test
with mid-p correction for comparisons between propor-
tions was used, as well as the Mann-Whitney Test to com-
pare differences in morbidity. All analyses were performed
using SPSS software (version 17).
The protocol was approved by the National Research
Ethics Committee (CONEP N° 520/2011; Register:
16,571 – Process: n° 25,000.115789/2011–94) and by
the Ethics Advisory Group at The Union, number: 11/11.
The protocol was also approved by each appropriate local
Institutional Review Board and Ethics Committee.
Results
A total of 175 eligible presumed DR-TB patients were
evaluated and 110 (63.0%) enrolled. Among the 65 ex-
cluded cases, the physicians used previous DST for deci-
sion making in 40 (DR: 39 and DS:1); 12 cases had no
DST results available, 11 cases had no additional clinical
and/or laboratory results available at the medical records,
and two had growing atypical mycobacteria (Fig. 1- Flow
diagram for Baseline Prove IT/5 sites 2011–2012). A
higher proportion of exclusion was observed at CRPHF-
Fiocruz-RJ (55.0%; 22/40) and lower at HP-SES-RGS
(14.0%; 6/43) (data not shown). The 65 excluded patients
were similar to the 110 included in all socio-demographic,
clinical and behavioral respects, except for higher school-
ing status (Table 1: Comparison of sociodemographic, be-
havior and clinical characteristics of presumed DR TB
cases included and excluded in the study).
Among those included were: 72 (65.5%) males, 62
(56.4%) aged 26 to 45 years, 20 (18.2%) with alcoholism,
83 (75.5%) current/ex-smokers, 37 (33.6%) admitted in
hospitals, 21 (19.0%) referred as staying in prison during
the last 2 years and, 3 (2.7%) type 2 diabetes mellitus.
HIV infection was identified in 12 (10.9%) and contact
with TB was shown in 50 (55.0%). TB in the past was
identified in 87 (79.1%), and among them, 31 (28.2%)
with more than three treatments (Table 1).
Time (in days) from triage to sputum collection was
0.0 (interquartile-IQR: 0–1.0); from triage to culture re-
sults was 32.5 (IQR: 14.7–63.0); from triage to DST re-
sults released by laboratory was 69.5 (IQR: 35.7–111.0);
from triage to DST results seen by the physicians was
97.0 (IQR: 64.2–143.0) and, from triage to adoption of
appropriate TB treatment, it was 1.0 (IQR: 0–41.2)
[Table 2 – Description of time from triage and different
medical and laboratory procedures among 110 presumed
DR TB suspects]. The median time (in days) from triage
to DST results released by the laboratory [133.0 (IQR:
95.0–184.0)] and, time from triage to DST results seen
by physicians [139.0 (IQR: 96.0–185.0)], were the longest
at IETAP-SES-RJ. The time (in days) from triage to DST
results released by laboratory [35.0 (IQR: 27.0–58.7)]
and time from triage to DST results seen by the phy-
sicians, [65.0 (IQR:36.0–86.0)] were the shortest at
HM-SES-CE. The median time (in days) from triage to
appropriate TB treatment was the longest at ICF-SES-SP
[35 (IQR: 35.0–99.0)], and the shortest at HP-SES-RS
[0 (IQR: 0–5.0)] (Table 2).
Culture results were provided by solid medium in 55
(45.1%) cases [LJ:2 (1.6%), Ogawa Kudo: 53 (43.4%)] and
MGIT960 in 67 (54.9%) cases. Smear positive/culture
positive and smear negative/culture positive cases were
identified in 96 (84.2%) and 16 (14.0%) cases, respectively.
Two cases did not have smears but had positive cultures.
DST results were available on 110 cases: 18 (16.4%) per-
formed by the PM and, 92 (83.6%) where the MGIT960
was used. DST results were provided by PM more fre-
quently in HSP-SES-RS. The median time (in days) of
laboratory released results of susceptibility testing was
similar with solid medium 70 (IQR: 63.0–113.5) as that
Table 1 Comparison of sociodemographic, behavior and clinical
characteristics of Presumed DR TB cases included and excluded in
the study (Continued)
Fever
Yes 67(60.9) 38(58.5) p = 0.61
No 39(35.5) 26(40.0)
IGN 4(3.6) 1(1.5)
Loss apetite
Yes 72(65.5) 47(72.3) p = 0.43
No 36(32.7) 18(27.7)
IGN 2(1.8) 0
Chest wheezing
Yes 57(51.8) 33(50.8) p = 0.63
No 46(41.8) 31(47.7)
IGN 7(6.4) 1(1.5)
Dyspneia
Yes 74(67.3) 35(53.8) p = 0.06
No 34(30.9) 30(46.2)
IGN 2(1.8) 0
Sneezing
Yes 45(40.9) 24(36.9) p = 0.41
No 59(53.6) 41(63.1)
IGN 6(5.5) 0
IGN ignored, NA not applicable
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observed with liquid medium 67 (IQR:33.5–114.5) [data
not shown].
The distribution of drug resistance is shown in Table 3
(Resistance for 1st line anti-TB drugs among M.tubercu-
losis isolates from presumed drug resistant TB cases en
5 Reference Centers – Brazil). Overall, DR and MDR-TB
rates were high: 51 (46.4%, 95% CI 37.3–55.6) and, 28
(25.5%, 95% CI 18.2–34.4) cases, respectively. Among
subjects not previously treated, 22 had MDR (25.3%, 95% CI
17.3%–35.4%). Among previously treated subjects, 6 had
MDR (26.1%, 95% CI 12.3–46.7). Resistance rates were par-
ticularly high for INH (n = 35, 40.2%, RIF n = 24, 27.6% and
EMB (n = 16, 18.4%). Among the 24 M tuberculosis strains
resistant to RMP, 23 (96.0%; 95% CI: 78.0–99.0) were also
resistant to INH.
Among 110 pDR-TB evaluated at triage, empirical treat-
ment was identified in 106 (96.0%). Arriving at triage, 36
(33.0%) patients referred by primary or secondary health
units were already taking anti-TB treatment, including 34
using standardized first line regimen and two with second
line drugs. At triage, TB drugs were prescribed by the at-
tending specialist as follows: 70 with first-line regimen
and 21 with second line drugs.
Comparing the demographics, behavior and clinical char-
acteristics of DR/MDR-TB to DS-TB cases and, MDR-TB
to DS-TB cases, each one, separately, presented the
following results: lower proportions of co-morbidity
(p = 0.05; p = 0.04); weight loss (p < 0.01; p < 0.01);
sweating (p = 0.04; p = 0.01) and, dyspnea (p = 0.05;
p = 0.02) [Table 4 – Demographic, behavior and clin-
ical characteristics of presumed drug resistant TB at
triage].
Comparing the radiological and Laboratory Results
and Treatment Prescription at Triage to DS-TB cases,
MDR TB cases were associated with lower proportion of
typical image on chest x ray (p = 0.03) [Table 5 – Radio-
logical and laboratory results and treatment prescription
at triage and during the follow-up in 110 presumed drug
resistant tuberculosis cases].
From the 110 pDR-TB included, 95 (86.0%) had been
followed-up until the 6th. month. Between those sub-
jects, 45 were DS-TB and 50 were DR/MDR-TB. Among
those 95 patients, 24 (25.3%: IC:17.5%–34.9%) changed
or initiated the treatment after DST results, totaling 16/29
(MDRTB), 5/21 (DR-TB), and 3/45 (DS-TB cases).
Comparing the treatment outcome in 95 pDR-TB cases
followed-up to DS-TB cases, DR/MDR and MDR-TB had
higher proportion, respectively, of changing or initiate
treatment after DST results (p = 0.05, p = 0.01) and
favourable outcome (p = 0.04 and p = 0.07) (Table 5).
Among all subjects followed-up, unfavorable outcome
was identified in 35 (36.8%; IC: 27.8–46.9), as follows: 2
(2.1%) died, 22 (23.0%) defaulted, 11 (11.6%) failed, and
4 (4.2%) were transferred to another health unit (Table 4).
The default rate was higher among DS-TB cases (20/45:
44.4%) than among DR/MDR-TB cases (2/46: 4.3%).
Table 2 Description of time from Triage and different medical and laboratorial procedures among 110 presumed DR TB suspects
Sites (type of culture used) To sputum
collection
To treatment
onset
To culture results to DST results
released by Lab
to DST results seen
by physicians
To appropriate
treatment
Messejana hospital N 32 32 32 32 31 32
(culture and DST by MGIT) Median 0 0 16.5 35 65 31
IQR 0–0 0–10.7 10–41,2 27–58.7 36–86 0–55
Clemente Ferreira Institute N 19 19 19 19 17 19
(culture and DST by MGIT) Median 0 0 11 59 128 35
IQR 0–1 0–0 9–18 26–115 57–159 35–99
Ary Parreiras hospital N 15 14 15 15 15 15
(culture and DST by MGIT = 14) Median 1 0 133 133 139 1
(culture and DST by PM = 1) IQR 0–3 0–1 89–180 95–184 96–185 0–77
Helio Fraga Reference Center N 17 17 17 13 9 17
(culture and DST by MGIT = 16) Median 0 0 43 87 141 1
(culture and DST by PM = 1) IQR 0–0 0–5 30.5–54.5 79–115.5 100–151 0–67.5
Partenon Hospital N 27 27 27 27 24 27
(culture and DST by MGIT = 11) Median 0 0 40 70 100.5 0
(culture and DST by PM = 16) IQR 0–1 0–1 30–63 63–113 70.2–149.7 0–5
All sites N 110 109 110 106 96 110
(culture and DST by MGIT = 92) Median 0 0 32.5 69.5 97 1
(culture and DST by PM = 18) IQR 0–1 0–1 14.7–63 35.7–111 64.2–143 0–41.2
DST drug susceptibility testing, IQR interquartile
Ramalho et al. BMC Infectious Diseases  (2017) 17:571 Page 6 of 13
Discussion
This is a descriptive study, in a high burden country, of
the health system approach at reference center level to
the investigation and management of patients suspected
of having drug resistant TB. At triage in those centers,
we observed a high rate (96.0%) of empirical treatment,
similar to that reported (96.0%) by Theron et al. [13]
among presumed drug sensitive and drug resistant
pulmonary TB cases detected by Xpert and higher than
that (59.0%) described by Yacobson et al. evaluating
presumed drug resistant TB cases [15].
Probably, physicians started anti-TB medication for
suspected drug resistant TB before the results of suscep-
tibility testing, due to previous delays experienced in the
release of such results by phenotypic tests. Nevertheless,
the median release time of DST results was 69.5 days, simi-
lar to (52–70 days) observed by Hannarah [10], Tukvadze
et al. [11] and Yadava et al. [14] and lower than described
(106–133 days) by Boheme et al. [12], Shin et al. [24], and
Gler et al. [25].
In our sample, the release median time for the results
of susceptibility testing was similar with solid medium
(70 days), such as that observed with liquid medium
(67 days), which in turn, is different to those results de-
scribed by Tukvadze et al. [11], where the average time
was lower (21.6 days) with liquid medium.
The median time from first admission to the Reference
Unit to start the appropriate treatment for DR-TB sus-
pects was 1.0 day, which is lower than that described
(67–133 days) by Hannarah et al. [10], Jacobson et al.
[15], Joh et al. [26], Shin [24] and Gler [25]. This result
may be different as the other studies did not describe
the relationship with empirical treatment and the change
of treatment after DST results were released.
We observed a large time variation from DST results
availability and the start of the appropriate treatment
Table 3 Resistance for 1st line anti-TB drugs among M.tuberculosis isolates from presumed Drug Resistant TB cases in 5 Reference
Centers - Brazil
Resistance Isolates from New cases (n = 87) Isolates from retreatment cases (n = 23)
N % (95% CI) N % (95% CI)
Fully susceptible 48 55.2(44.7–65.2) 11 50.0(30.7–69.3)
Any resistancea
INH 35 40.2(30.5–50.7) 10 45.4(26.9–63.4)
RMP 24 27.6(19.3–37.8) 7 31.8(16.2–52.8)
EMB 16 18.4(11.5–27.9) 1 4.5(0.1–29.0)
SM 14 16.1(9.7–25.3) 4 18.9(6.7–39.1)
PZA 6 6.9(2.9–14.5) 1 4.5(0.1–29.0)
Multidrug resistance 22 25.3(17.3–35.4) 6 27.3(12.9–48.4)
RMP + INH 7 8.1(3.7–15.5) 3 13.6(3.9–34.2)
RMP + INH + EMB 2 2.3(0.1–6.7) − −
RMP + INH + SM 1 1.2(0.05–6.7) 2 9.1(1.3–29.0)
RMP + INH + EMB + SM 7 8.1(3.7–15.5) − −
Other forms of Resistance 5 5.7(2.2–13.1) 1 4.5(0.1–29.0)
INH only 6 6.9(2.9–14.5) 2 9.1(1.3–29.0)
RMP only 1 1.2(0.05–6.7) − −
SM only 1 1.2(0.05–6.7) 1 4.5(0.1–29.0)
EMB only 1 1.2(0.05–6.7) − −
PZA only 1 1.2(0.05–6.7) − −
Number of drugs to which patients were resistant
0 48 55.2(44.7–65.2) 11 50.0(30.7–69.3)
1 10 11.5(6.2–20.1) 3 13.6(3.9–34.2)
2 13 14.9(8.8–24.0) 4 18.9(6.7–39.1)
3 5 5.7(2.2–13.1) 4 18.9(6.7–39.1)
4 11 12.6(7.0–21.4) 1 50.0(30.7–69.3)
RMP rifampicin, INH isoniazid, EMB ethambutol, SM streptomycin, PZA pyrazinamid, CI confidence intervals
aAny resistance indicates resistance to the anti-tuberculosis medication tested, independent of resistance results to other medications
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Table 4 Demographic, Behaviour and Clinical Characteristics of Presumed Drug Resistant TB at Triage
DS-TB DR/MDR-TB MDR-TB p value
N (%) N (%) OR(95% CI) p value N (%) OR(95% CI)
Demographic Characteristics
Sex
Male 39(66.1) 33(64.7) 1.0 (Reference) p = 0.87 20(64.5) 1.0 (Reference) p = 0.88
Female 20(33.9) 18(35.3) 0.94(0.42–2.06) 11(35.5) 1.07(0.43–2.67)
Age
< 25 9(15.3) 6(11.8) 1.0 (Reference) 4(12.9) 1.0 (Reference)
26–45 34(57.6) 28(54.9) 0.81(0.25–2.55) p = 0,71 18(58.1) 0.83(0.22–3.10) p = 0.79
> 45 16(27.1) 17(33.3) 0.62(0.18–2.16) p = 0.46 9(29.0) 0.79(0.18–3.31) p = 0.74
Race
White 20(33.9) 26(50.9) 1.0 (Reference) p = 0.07 16(51.6) 1.0 (Reference) p = 0.10
Non White 39(63.1) 25(49.1) 2.02(0.94–4.37) 15(48.4) 2.08(0.85–5.05)
Schooling (Patient)
< 8 years 54(91.5) 44(86.3) 1.0 (Reference) p = 0.54 27(87.1) 1.0 (Reference) p = 0.61
> 8 years 4(6.8) 5(9.8) 0.65(0.16–2.57) 3(9.7) 2.66(0.14–3.20)
IGN 1(1.7) 2(3.9) - 1(3.2)
Behavhiour characteristics
Smoker
Current 30(50.8) 18(35.3) 1.0 (Reference) 10(32.3) 1.0 (Reference) p = 0.10
Ex 18(30.5) 17(33.3) 0.63(0.26–1.53) p = 0.31 11(35.4) 0.54(0.19–1.53) p = 0.25
Never 10(16.8) 15(29.4) 0.40(0.14–1.07) p = 0.06 10(32.3) 0.33(0.10–1.03)
IGN 1(1.7) 1(2.0) 0
Alcoholism (CAGE)
Yes 13(22.0) 7(13.7) 1.0 (Reference) p = 0.26 3(9.7) 1.0 (Reference)
No 46(78.0) 44(86.3) 0.56(0.20–1.54)
-
28(90.3 0.37(0.09–1.44) p = 0.05
Admission hospital last 2 years
Yes 22(37.3) 15(29.4) 1.0 (Reference) p = 0.34 8(25.8) 1.0 (Reference) p = 0.24
No 36(61.0) 36(70.6) 0.68(0.30–1.52) 23(74.2) 0.56(0.21–1.49)
IGN 1(1.7) 0 - 0
Admission prison last 2 years
Yes 14(23.7) 7(13.7) 1.0 (Reference) p = 0.18 5(16.1) 1.0 (Reference) p = 0.40
No 45(76.3) 44(86.3) 0.51(0.18–1.38)
-
26(83.9) 0.61(0.19–1.91)
Admission in Shelters last 2 years
Yes 5(8.5) 3(5.9) 1.0 (Reference) p = 0.60 3(9.7) 1.0 (Reference) p = 1.00
No 53(89.8) 47(92.1) 0.67(0.15–2.98) 27(87.1) 1.17(0.26–5.30)
IGN 1(1.7) 1(2.0) - 1(3.2)
Clinical Characteristics
Contact of pulm TB
Yes 29(49.2) 26(50.9) 1.0 (Reference) p = 0.95 19(61.3) 1.0 (Reference) p = 0.17
No 24(40.7) 21(41.2) 1.02(0.46–2.25) 8(25;8) 1.96(0.73–5.27)
IGN 6(10.1) 4(7.9) - 4(12.9)
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within the 5 reference centers. Major delays in the DST
results released by laboratories and seen by physicians
occurred in the sites that lacked DST in local laboratories
and had no computerized system to release the informa-
tion to the health care team right away. This confirms that
the organization of services should be taken into account
when evaluating the incorporation of new diagnostic
technologies for TB as commented on by Creswel et al.
[16] when implementing Xpert MTB Rif in 9 countries
and by Jacobson and Yannarah on the implementation
of MDRTB plus in South Africa [10, 15].
High proportions of drug resistant TB (46.0%) and
multidrug-resistant TB (25.5%) were found, even in those
not previously treated. This results were similar to those
described in other studies in which patients with sus-
pected drug resistant TB were evaluated [3, 24, 27, 28].
Among the M. tuberculosis strains resistant to rifampicin,
96.0% were resistant to INH, such as described by
Table 4 Demographic, Behaviour and Clinical Characteristics of Presumed Drug Resistant TB at Triage (Continued)
TB in the past
Yes 48(81.3) 39(76.5) 1.0 (Reference) p = 0.66 23(74.2) 1.0 (Reference) p = 0.60
No 11(18.7) 11(21.6) 0.81(0.31–2.07) 7(22.6) 0.75(0.25–2.19)
IGN 0 1(1.9) - 1(3.2)
Number treat in the past
= > 3 16(27.1) 15(29.4) 1.0 (Reference) p = 0.62 9(29.0) 1.0 (Reference) p = 0.63
< 3 32(54.2) 24(47.1) 1.25(0.51–3.01) 14(45.2) 1.28(0.45–3.60)
IGN 11(18.7) 12(23.5) - 8(25.8)
Outcome TB treat in the past
Cure/complete 17(28.8) 8 (15.7) 1.0 (Reference) p = 0.17 3(9.6) 1.0 (Reference) p = 0.06
Defaulting/failure 30(50.8) 28(54.9) 0.5(0.18–1.35) 19(61.3) 0.27 (0.07–1.08)
IGN 12(20.3) 15(29.4) 9(29.1)
Cough/Expectoration
Yes 52(88.1) 43(84.3) 1.0 (Reference) p = 0.40 23(74.3) 1.0 (Reference) p = 0.06
No 6(10.2) 8(15.7) 0.62(0.19–1.92) 8(25;8) 0.33(0.10–1.06)
IGN 1(1.7) 0 - 0
Hemoptysis
Yes 13(22.0) 13(25.5) 1.0 (Reference) p = 0.70 6(19.3) 1.0 (Reference) p = 0.73
No 45(76.3) 38(74.5) 1.18(0.49–2.86) 25(80.7) 0.83(0.28–2.45)
IGN 1(1.7) 0 - 0
Fever
Yes 38(64.4) 29(56.8) 1.0 (Reference) p = 0.29 17(54.8) 1.0 (Reference) p = 0.22
No 18(30.5) 21(41.2) 0.65(0.29–1.44) 14(45.2) 0.57(0.23–1.41)
IGN 3(5.1) 1(2.0) - 0
Weight loss
Yes 49(83.1) 26(50.9) 4.71(1.96–11.3) p < 0.01 14(45.2) 1.0 (Reference) p < 0.01
No 10(16.9) 25(49.1) 1.0 (Reference) 17(54.8) 5.95(2.23–15.87)
Sweating
Yes 43(72.9) 25(49.0) 2.58(1.12–5.95) p = 0.04 13(41.9) 1.0 (Reference) p = 0.01
No 14(23.6) 21(41.2) 1.0 (Reference) 15(48.4) 3.54(1.36–9.22)
IGN 2(2.5) 5(9.8) - 3(9.7)
Dyspneia
Yes 44(74.6) 27(52.9) 2.39(1.05–5.44) p = 0.05 15(48.4) 1.0 (Reference) p = 0.02
No 15(25.4) 22(43.1) 1.0 (Reference) 16(51.6) 3.18(1.28–7.93)
IGN 0 2(4.0) 0
IGN ignored, NA not applicable, MDR multidrugresistant, DR drug resistant, DS drug sensitive
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Table 5 Radiological and Laboratory Results and Treatment Prescription at Triage and during the follow-up in 110 Presumed Drug
Resistant Tuberculosis Cases
Variable DS-TB DR/MDR-TB MDR-TB p value
N (%) N (%) OR(95% CI) p value N (%) OR(95% CI)
Treatment and Laboratory results at Triage
AFB at triagem
Pos 53(89.8) 41(80.4) 1.0 (Reference) p = 0.34 24(77.4) 1.0 (Reference) p = 0.19
Neg 6(10.2) 8(15.7) 0.58(0.18–1.80) 6(19.3) 0.45 (0.13–1.55)
IGN 0 2(3.9) 1(3.2)
HIV testing result
Positive 9(15.3) 3(5.9) 1.0 (Reference) p = 0.06 3(9.7) 1.0 (Reference) p = 0.33
Negative 27(45.8) 34(62.7) 0.26(0.06–1.07) 18(56.1) 0.50 (0.11–2.10)
IGN 11(38.9) 14(27.4) - 10(32.2)
Chest X Ray(Images)
Typical 56(94.8) 45(88.2) 1.0 (Reference) p = 0.08 25(80.6) 1.0 (Reference) p = 0.01
Compatible 1(1.9) 6(11.8) 0.13(0.01–1.15) 6(19.4) 0.07(0.008–0.65)
Atipical 2(3.3) 0 - 0
Cavitation
Yes 52(88.1) 40(78.4) 1.0 (Reference) p = 0.16 23(74.2) 1.0 (Reference) p = 0.19
No 6(10.0) 10(19.5) 0.46(0.15–1.37) 7(22.6) 0.37 (0.11–1.25)
IGN 1(1.9) 1(1.9) 1(3.2)
Empirical treament
Yes 58 (98.3) 48(94.1) 1.0 (Reference) p = 0.51 28(90.3) 1.0 (Reference) p = 0.23
1st line drugs 51 34 0.27(0.02–2.73) 12 0.16(0.01–1.61)
2nd line drugs 7 14 16
No 1 (1.7) 3 (5.9) 3(9.7)
Anti_TB drugs prescribed at triage
Maintained the regimen 18(30.5) 18(35.3) 1.0(Reference) p = 0.59 12(38.7) 1.0 (Reference) p = 0.43
Start new TB regimen 41(69.5) 33(64.7) 1.24(0.56–2.76) 19(61.3) 1.44(0.57–3.57)
Treatment and Laboratory results among 95 pDR-TB Followed-up
Adverse reaction
Yes 7(15.6) 11(22.0) 1.0 (Reference) p = 0.88 8(27.6) 1.0 (Reference) p = 0.82
No 20(44.5) 34(68.0) 0.92(0.30–2.76) 20(68.9) 1.14(0.34–3.75)
IGN 18(40.0) 5(10.0) 1(3.4)
Change of treat
Yes 9(20.0) 27(54.0) 1.0 (Reference) p = 0.03 20(68.9) 1.0 (Reference) p < 0.01
Use DST results 3 21 2.85(1.06–7.60) 16 4.69(1.53–14.34)
Other 6 6 4
No 19(42.0) 20(40.0) 9(31.1)
IGN 17(37.8) 3(6.0)
AFB 6th month
Positive 2(4.5) 6(12.0) 1.0 (Reference) p = 0.35 4(13.8) 1.0 (Reference) p = 0.49
Negative 17(37.8) 23(46.0) 2.21(0.39–12.36) 12(41.4) 2.80(0.44–18.0)
IGN 26(57.8) 21 (42.0) 13 (44.8)
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Kurbatova [29] suggesting that rifampicin resistance can
be used as a proxy for MDR-TB.
The factors associated with the occurrence of MDR-
TB observed in our study (lower sweating, presence of
comorbidities and typical chest x ray images) were simi-
lar to those described by Martinez [30]. However, we ob-
served no association of MDR-TB with other variables
identified in other studies, such as TB in the past, contact
with TB, cavitation in chest X-ray, alcoholism, smoking,
type 2 diabetes mellitus, HIV infection, and prison in-
mates [28, 30–34]. Such results may reflect the small sam-
ple size and low frequency of these variables in MDR-TB
cases.
In our study, DR and MDR TB cases had higher propor-
tions changing or initiating treatment after DST results
and higher favorable outcomes, similar to those described
(44.0%–57.0%) by Yacobson [15] and Gler [25].
Compared to DS-TB cases, no difference was observed
in culture conversion at the sixtieth month in patients
with drug resistant TB, which is a different result from
that described by others [10, 15, 30]. At the sixtieth
month of follow-up, it was observed a high defaulting
rate (23.0%) similar to that described (26.0%) by Tockzek
et al. [35] when evaluating 10 studies where no direct
observed therapy was performed.
The strengths of our study include: (a) standardized
screening of presumed DR TB patients enrolled from 5
Reference Sites in four States; (b) the culture and DST
were done in a reference laboratory that follows the
standard WHO guidelines and, (c) the personnel per-
forming the DST were unaware of the patient’s clinical
or radiographic findings. The limitations of this study
are that it relies on small sample size from metropolitan
areas within four States, which may not be representative
of the whole country, and that we included only patients
with culture confirmed TB. Additionally, the exclusion of
individuals at high risk for MDR TB that doctors used a
previous DST result to manage treatment, may explain
the lack of association with factors such as previous TB,
contact with TB, cavitation in chest X-ray, alcoholism,
smoking, type II diabetes mellitus, as described in the
literature.
Conclusions
This study shows a high rate of empirical treatment and
long delays for DST results. Favorable treatment outcomes
among DR and MDR-TB patients was due to the adoption
of an appropriate treatment, mainly among those that
started first line regimens empirically. Improvements in
the flow of patients and/or clinical samples to referral cen-
ters and, use of triage clinical procedures at referral level
with higher performance, may be helpful to provide a
more appropriate case management.
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